Global Mantle Cell Lymphoma Epidemiology and Patient-Based Market 2016 - Forecasts to 2025 - Research and Markets

DUBLIN, August 16, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "Nhl: Mantle Cell Lymphoma: Epidemiology and Patient-Based Market Forecasts, Treatment Algorithm, and Marketed and Pipeline Drug Analysis" report to their offering.

An increase in incident cases, combined with the expanded use of costly treatments such as Imbruvica and Revlimid, will drive the growth of the mantle cell lymphoma (MCL) market during 2016-25.

This report addresses the following questions:

- What will be driving the growth of the MCL market during 2016-25?

- Which markets will experience the biggest growth?

- Which branded therapies will have the largest impact on the MCL market?

- What is the overall market potential for Imbruvica and Revlimid?

- When will generic and biosimilar therapies enter the market and what impact will they have on revenues?

Key Topics Covered:

FORECAST: MANTLE CELL LYMPHOMA

- Market Overview and Trends

- Market Definition and Methodology

- Imbruvica (ibrutinib)

- Revlimid (lenalidomide)

- Rituxan (rituximab)

- Torisel (temsirolimus)

- Velcade (bortezomib)

- Primary Research Methodology

TREATMENT: MANTLE CELL LYMPHOMA

- Primary Research Methodology

- Disease Definition and Diagnosis

- Patient Segmentation

- Country Treatment Trees

- Current Treatment Options

- Prescribing Trends: Localized Stage (I/II)

- Prescribing Trends: Bulky Stage (II/III/IV)

EPIDEMIOLOGY: MANTLE CELL LYMPHOMA

- Disease Background

- Sources and Methodology

- Forecast: NHL Overall

- Forecast: NHL Subtypes (incl. DLBCL, FL, and MCL)

- Epidemiologist Insight

- Strengths and Limitations

MARKETED DRUGS: MANTLE CELL LYMPHOMA

- Product profile: Imbruvica

- Product profile: Revlimid

- Product profile: Rituxan

- Product profile: Torisel

- Product profile: Treanda

- Product profile: Velcade

PIPELINE: MANTLE CELL LYMPHOMA

- Product profile (late stage): Darzalex.

- Product profile (late stage): Gazyva

- Product profile (late stage): KTE-C

- Product profile (late stage): Kyprolis

For more information about this report visit http://www.researchandmarkets.com/research/tgpchr/nhl_mantle_cell

Related Topics: Lymphoma Drugs

Media Contact:

Laura Wood, Senior Manager

[e-mail]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call [phone]

U.S. Fax: [phone]

Fax (outside U.S.): [phone]